Prosonix Extends Series B Financing, Plans Generic Fluticasone Filing
This article was originally published in The Pink Sheet Daily
Executive Summary
Prosonix receives an extra $9 million for its Series B round as it changes business strategy from contract research to the development of generic respiratory products, based on a novel particle-engineering technology for inhaled powders.